{"url_path":"/sec/dftx/8-k/2026-06-22/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 ****Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1813814/0001104659-26-076091-index.html","accession_number":"0001104659-26-076091","cik":"0001813814","ticker":"DFTX","issuer_name":"Definium Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1813814/0001104659-26-076091-index.html","primary_entity_key":"0001813814","primary_entity_name":"Definium Therapeutics, Inc."},"word_count":87,"has_tables":true,"body_markdown":"**Item 9.01****Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits.\n\n \n\n**Exhibit No.**\n \n**Description**\n\n[99.1](tm2618434d1_ex99-1.htm)\n \n[Press Release, dated June 22, 2026](tm2618434d1_ex99-1.htm)\n\n[99.2](tm2618434d1_ex99-2.htm)\n \n[Emerge Topline Data Presentation, dated June 22, 2026](tm2618434d1_ex99-2.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n \n \nDEFINIUM THERAPEUTICS, INC.\n\n \n \n \n \n\nDate:\nJune 22, 2026\nBy:\n/s/ Robert Barrow\n\n \n \n \nName: Robert\nBarrow\n\n \n \n \nTitle:   Chief Executive Officer"}